T cells assemble lentivirus to solve local delivery of stable gene therapy

Posted on
t-cells-assemble-lentivirus-to-solve-local-delivery-of-stable-gene-therapy
T cells assemble lentivirus to solve local delivery of stable gene therapy

References

  1. Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open. 2 (5), e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535 (2019).

    Google Scholar 

  2. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229–263. https://doi.org/10.3322/caac.21834 (2024).

    Google Scholar 

  3. Wang, M. M., Coupland, S. E., Aittokallio, T. & Figueiredo, C. R. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br. J. Cancer. 129, 1212–1224. https://doi.org/10.1038/s41416-023-02361-4 (2023).

    Google Scholar 

  4. Chamoto, K., Hatae, R. & Honjo, T. Current issues and perspectives in PD-1 Blockade cancer immunotherapy. Int. J. Clin. Oncol. 25, 790–800 (2020).

    Google Scholar 

  5. Said, S. S. & Ibrahim, W. N. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics 15 (4), 1143. https://doi.org/10.3390/pharmaceutics15041143 (2023).

    Google Scholar 

  6. Iriguchi, S. & Kaneko, S. Toward the development of true off-the-shelf synthetic T-cell immunotherapy. Cancer Sci. 110, 16–22 (2019).

    Google Scholar 

  7. Wang, G. et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat. Immunol. 20, 1494–1505. https://doi.org/10.1038/s41590-019-0500-4 (2019).

    Google Scholar 

  8. Macarrón Palacios, A., Korus, P., Wilkens, B. G. C., Heshmatpour, N. & Patnaik, S. R. Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges. Front. Genome Ed. 1, 6,1342193. https://doi.org/10.3389/fgeed.2024.1342193 (2024).

    Google Scholar 

  9. Santiago-Ortiz, J. L. & Schaffer, D. V. Adeno-associated virus (AAV) vectors in cancer gene therapy. J. Control Release. 28, 240:287–301. https://doi.org/10.1016/j.jconrel.2016.01.001 (2016).

    Google Scholar 

  10. Zhang, Y. & Wu, Z. Y. Gene therapy for Monogenic disorders: challenges, strategies, and perspectives. J. Genet. Genomics. 51 (2), 133–143. https://doi.org/10.1016/j.jgg.2023.08.001 (2024).

    Google Scholar 

  11. Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-Mediated In vivo gene therapy. Mol. Ther. Methods Clin. Dev. 1, 8:87–104. https://doi.org/10.1016/j.omtm.2017.11.007 (2017).

    Google Scholar 

  12. Luo, J. et al. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett. 28 (356(2 Pt B)), 347–356. https://doi.org/10.1016/j.canlet.2014.10.045 (2015).

    Google Scholar 

  13. Wang, J. H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Sig Transduct. Target. Ther. 9, 78. https://doi.org/10.1038/s41392-024-01780-w (2024).

    Google Scholar 

  14. Matsunaga, W. & Gotoh, A. Adenovirus as a vector and oncolytic virus. Curr. Issues Mol. Biol. 2,45, 4826–4840. https://doi.org/10.3390/cimb45060307 (2023).

    Google Scholar 

  15. Bulcha, J. T. et al. Viral vector platforms within the gene therapy landscape. Sig Transduct. Target. Ther. 6, 53. https://doi.org/10.1038/s41392-021-00487-6 (2021).

    Google Scholar 

  16. Jin, L., Zeng, X., Liu, M., Deng, Y. & He, N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics 4 (3), 240–255. https://doi.org/10.7150/thno.6914 (2014).

    Google Scholar 

  17. Zu, H. & Gao, D. Non-viral vectors in gene therapy: recent Development, Challenges, and prospects. AAPS J. 23, 78. https://doi.org/10.1208/s12248-021-00608-7 (2021).

    Google Scholar 

  18. Schiller, L. T., Lemus-Diaz, N., Ferreira, R., Böker, R., Gruber, J. & K.O. & Enhanced production of Exosome-Associated AAV by overexpression of the tetraspanin CD9. Mol. Ther. Methods Clin. Dev. 29, 9:278–287. https://doi.org/10.1016/j.omtm.2018.03.008 (2018).

    Google Scholar 

  19. Pilgrim, S. et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther. 10 (24), 2036–2045. https://doi.org/10.1038/sj.gt.3302105 (2003).

    Google Scholar 

  20. Wang, B. et al. Magnetotactic Bacteria-Based Drug-Loaded micromotors for highly efficient magnetic and biological Double-Targeted tumor therapy. ACS Appl. Mater. Interfaces. 15 (2), 2747–2759. https://doi.org/10.1021/acsami.2c19960 (2023).

    Google Scholar 

  21. Felfoul, O. et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nat. Nanotechnol. 11, 941–947 (2016).

    Google Scholar 

  22. Faghihkhorasani, A. et al. The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection. Virol. J. 20, 222 (2023).

    Google Scholar 

  23. Xie, F. et al. Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy. Adv. Sci. (Weinh). 6 (24), 1901779. https://doi.org/10.1002/advs.201901779 (2019).

    Google Scholar 

  24. Karjoo, Z., Chen, X. & Hatefi, A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 99(Pt A) 113–128. https://www.sciencedirect.com/science/article/abs/pii/S0169409X15001027 (2016).

  25. Choi, B. D. et al. CAR-T cells secreting bites circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049–1058 (2019).

    Google Scholar 

  26. Yeku, O. O. et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).

    Google Scholar 

  27. Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).

    Google Scholar 

  28. Li, L. et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep. 12, 12506 (2022).

    Google Scholar 

  29. Wang, Y. et al. Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer. Sig Transduct. Target. Ther. 8, 399 (2023).

    Google Scholar 

  30. Zhang, Y. et al. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy. J. Transl Med. 19, Article82 (2021).

    Google Scholar 

  31. Pascual-Pasto, G. et al. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat. Commun. 15, 7141 (2024).

    Google Scholar 

  32. Sachdeva, M. et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat. Commun. 10, 5100. https://doi.org/10.1038/s41467-019-13088-3 (2019).

    Google Scholar 

  33. Tristán-Manzano, M. et al. Externally-Controlled systems for immunotherapy: from bench to bedside. Front. Immunol. 11, 2044. https://doi.org/10.3389/fimmu.2020.02044 (2020).

    Google Scholar 

  34. Zeng, M., Zhang, W., Li, Y. & Yu, L. Harnessing adenovirus in cancer immunotherapy: evoking cellular immunity and targeting delivery in cell-specific manner. Biomark. Res. 12, 36. https://doi.org/10.1186/s40364-024-00581-1 (2024).

    Google Scholar 

  35. Schenkel, J. M. & Pauken, K. E. Localization, tissue biology and T cell state — implications for cancer immunotherapy. Nat. Rev. Immunol. 23, 807–823. https://doi.org/10.1038/s41577-023-00884-8 (2023).

    Google Scholar 

  36. Sertkaya, H. et al. HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency. Sci. Rep. 11, Article12067 (2021).

    Google Scholar 

  37. Böker, K. O. et al. The impact of the CD9 tetraspanin on lentivirus infectivity and exosome secretion. Mol. Ther. 26 (2), 634–647. https://doi.org/10.1016/j.ymthe.2017.11.008 (2018).

    Google Scholar 

  38. Rocha-Perugini, V., Sánchez-Madrid, F. & Martínez Del Hoyo, G. Function and dynamics of tetraspanins during antigen recognition and immunological synapse formation. Front. Immunol. 6, Article653 (2015).

    Google Scholar 

  39. Ferreira, M. V., Cabral, E. T. & Coroadinha, A. S. Progress and perspectives in the development of lentiviral vector producer cells. Biotechnol. J. 16(1), Article 2000017 (2021).

  40. Dautzenberg, I. J. C., Rabelink, M. J. W. E. & Hoeben, R. C. The stability of envelope-pseudotyped lentiviral vectors. Gene Ther. 28, 89–104 (2021).

    Google Scholar 

  41. Sweeney, N. P. & Vink, C. A. The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titre. Mol. Ther. Methods Clin. Dev. 21, 574–584 (2021).

    Google Scholar 

  42. Kulemzin, S. V. et al. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines. BMC Med. Genomics. 12 (Suppl 2), 44. https://doi.org/10.1186/s12920-019-0489-4 (2019).

    Google Scholar 

  43. Cawthorne, C., Swindell, R., Stratford, I. J., Dive, C. & Welman, A. Comparison of Doxycycline delivery methods for Tet-inducible gene expression in a subcutaneous xenograft model. J. Biomol. Tech. 18 (2), 120–123 (2007).

    Google Scholar 

  44. Randolph, L. N. et al. An all-in-one, Tet-On 3G inducible piggybac system for human pluripotent stem cells and derivatives. Sci. Rep. 7, 1549 (2017).

    Google Scholar 

  45. Hu, Y. et al. γδ T cells: origin and fate, subsets, diseases and immunotherapy. Sig Transduct. Target. Ther. 8, 434 (2023).

    Google Scholar 

  46. Woodland, D. & Kohlmeier, J. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9, 153–161. https://doi.org/10.1038/nri2496 (2009).

    Google Scholar 

  47. Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, C. & Schillaci, R. I. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Front. Oncol. 13, 1135456. https://doi.org/10.3389/fonc.2023.1135456 (2023).

    Google Scholar 

  48. Nabhan, M. et al. Deciphering the tumour immune microenvironment cell by cell. Immunooncol Technol. 18, 100383. https://doi.org/10.1016/j.iotech.2023.100383 (2023).

    Google Scholar 

  49. Slaney, C. Y., Kershaw, M. H. & Darcy, P. K. Trafficking of T cells into tumors. Cancer Res. 74 (24), 7168–7174. https://doi.org/10.1158/0008-5472.CAN-14-2458 (2014).

    Google Scholar 

  50. Lesch, S. et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng. 5, 1246–1260. https://doi.org/10.1038/s41551-021-00737-6 (2021).

    Google Scholar 

  51. Liu, L. et al. Engineering chimeric antigen receptor T cells for solid tumour therapy. Clin. Transl Med. 12 (12), e1141. https://doi.org/10.1002/ctm2.1141 (2022).

    Google Scholar 

  52. Kazemi, M. H. et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front. Immunol. 13, 1018962. https://doi.org/10.3389/fimmu.2022.1018962 (2022).

    Google Scholar 

  53. Arjomandnejad, M., Kopec, A. L. & Keeler, A. M. CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Biomedicines. 10(2), 287 (2022). https://doi.org/10.3390/biomedicines10020287

  54. Kaljanac, M. & Abken, H. Do Treg speed up with cars? Chimeric antigen receptor Treg engineered to induce transplant tolerance. Transplantation 107 (1), 74–85. https://doi.org/10.1097/TP.0000000000004316 (2023).

    Google Scholar 

  55. Requejo Cier, C. J., Valentini, N. & Lamarche, C. Unlocking the potential of tregs: innovations in CAR technology. Front. Mol. Biosci. 10, 1267762. https://doi.org/10.3389/fmolb.2023.1267762 (2023).

    Google Scholar 

  56. Huang, Y. et al. Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat. Commun. 11 (1), 622. https://doi.org/10.1038/s41467-020-14425-7 (2020).

    Google Scholar 

  57. Liu, Y. T. & Sun, Z. J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11, 5365–5386. https://doi.org/10.7150/thno.58390 (2021).

    Google Scholar 

  58. Donnadieu, E., Dupré, L., Pinho, L. G. & Cotta-de-Almeida, V. Surmounting the Obstacles that impede effective CAR T cell trafficking to solid tumors. J. Leukoc. Biol. 108 (4), 1067–1079. https://doi.org/10.1002/JLB.1MR0520-746R (2020).

    Google Scholar 

  59. Visioni, A. et al. Intra-arterial versus intravenous adoptive cell therapy in a mouse tumor model. J. Immunother. 41 (7), 313–318. https://doi.org/10.1097/CJI.0000000000000235 (2018).

    Google Scholar 

  60. Petersen, C. C., Petersen, M. S., Agger, R. & Hokland, M. E. Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection. J. Immunother. 29 (3), 241–249. https://doi.org/10.1097/01.cji.0000203078.97493.c3 (2006).

    Google Scholar 

  61. Palmer, D. C. et al. Vaccine-stimulated, adoptively transferred CD8 + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173 (12), 7209–7216. https://doi.org/10.4049/jimmunol.173.12.7209 (2004).

    Google Scholar 

  62. Belete, T. M. The current status of gene therapy for the treatment of cancer. Biologics 15, 67–77. https://doi.org/10.2147/BTT.S302095 (2021).

    Google Scholar 

  63. Gadi, V. et al. Vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7, 1738–1743. https://doi.org/10.1038/sj.gt.3301286 (2000).

    Google Scholar 

  64. Sorscher, E. J., Hong, J. S., Parker, W. B., Pre-clinical and & clinical validation of an anti-cancer modality that ablates refractory. low growth fraction tumors. Trans. Am. Clin. Climatol Assoc. 127, 59–70 (2016).

  65. Roy, D. G. & Bell, J. C. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother. 2, 47–56. https://doi.org/10.2147/OV.S36623 (2013).

    Google Scholar 

  66. Albers, J., et al. A versatile modular vector system for rapid combinatorial mammalian genetics. J Clin Invest. Mar 9. pii: 79743. (2015). https://doi.org/10.1172/JCI79743 PubMed 25751063.

  67. Simeonov, D. R., et al. Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature. Epub 2017 Aug 30. (2017). https://doi.org/10.1038/nature23875 PubMed 28854172.

  68. Jutz, S. et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF-kappaB, NFAT and AP-1. J Immunol Methods. (2016). https://pubmed.ncbi.nlm.nih.gov/26780292/ PubMed 26780292.

  69. Park, J. et al. Recording of elapsed time and temporal information about biological events using Cas9. Cell. Jan 28. pii: S0092-8674(21)00014-3.  https://www.ncbi.nlm.nih.gov/pubmed/33539780014. (2021). PubMed 33539780.

  70. SnapGene® (ed) software (from Dotmatics; available at snapgene.com).

Download references

Related Posts